102 related articles for article (PubMed ID: 7531318)
1. Binding in vitro of phosphotyrosine-containing proteins to pp60c-src SH2 domain does not correlate with CEF transformation.
Boeuf H; Murphy J; Bibbins KB; Varmus HE
Oncogene; 1995 Feb; 10(3):433-8. PubMed ID: 7531318
[TBL] [Abstract][Full Text] [Related]
2. Reduced phosphotyrosine binding by the v-Src SH2 domain is compatible with wild-type transformation.
Tian M; Martin GS
Oncogene; 1996 Feb; 12(4):727-34. PubMed ID: 8632894
[TBL] [Abstract][Full Text] [Related]
3. Regulation of c-Src tyrosine kinase activity by the Src SH2 domain.
Liu X; Brodeur SR; Gish G; Songyang Z; Cantley LC; Laudano AP; Pawson T
Oncogene; 1993 May; 8(5):1119-26. PubMed ID: 7683128
[TBL] [Abstract][Full Text] [Related]
4. The SH3 and SH2 domains are capable of directing specificity in protein interactions between the non-receptor tyrosine kinases cSrc and cYes.
Summy JM; Guappone AC; Sudol M; Flynn DC
Oncogene; 2000 Jan; 19(1):155-60. PubMed ID: 10644991
[TBL] [Abstract][Full Text] [Related]
5. Regulation of the cellular src protein tyrosine kinase: interactions of the carboxyl terminal sequences residing between the kinase domain and tyrosine-527.
Cobb BS; Parsons JT
Oncogene; 1993 Nov; 8(11):2897-903. PubMed ID: 7692368
[TBL] [Abstract][Full Text] [Related]
6. Dissection of the energetic coupling across the Src SH2 domain-tyrosyl phosphopeptide interface.
Lubman OY; Waksman G
J Mol Biol; 2002 Feb; 316(2):291-304. PubMed ID: 11851339
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine phosphorylation of a 120,000 dalton membrane-associated protein by the neural form of pp60c-src, pp60c-src+.
Flynn DC; Schaller MD; Parsons JT
Oncogene; 1992 Mar; 7(3):579-83. PubMed ID: 1372401
[TBL] [Abstract][Full Text] [Related]
8. An RNA-binding protein associated with Src through its SH2 and SH3 domains in mitosis.
Taylor SJ; Shalloway D
Nature; 1994 Apr; 368(6474):867-71. PubMed ID: 7512694
[TBL] [Abstract][Full Text] [Related]
9. Molecular interactions of the Src homology 2 domain protein Shb with phosphotyrosine residues, tyrosine kinase receptors and Src homology 3 domain proteins.
Karlsson T; Songyang Z; Landgren E; Lavergne C; Di Fiore PP; Anafi M; Pawson T; Cantley LC; Claesson-Welsh L; Welsh M
Oncogene; 1995 Apr; 10(8):1475-83. PubMed ID: 7537362
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation of growth factor receptor binding protein-2 by pp60c-src tyrosine kinase.
Jones DA; Benjamin CW
Arch Biochem Biophys; 1997 Jan; 337(2):143-8. PubMed ID: 9016807
[TBL] [Abstract][Full Text] [Related]
11. Recognition of a high-affinity phosphotyrosyl peptide by the Src homology-2 domain of p56lck.
Eck MJ; Shoelson SE; Harrison SC
Nature; 1993 Mar; 362(6415):87-91. PubMed ID: 7680435
[TBL] [Abstract][Full Text] [Related]
12. A target for Src in mitosis.
Fumagalli S; Totty NF; Hsuan JJ; Courtneidge SA
Nature; 1994 Apr; 368(6474):871-4. PubMed ID: 7512695
[TBL] [Abstract][Full Text] [Related]
13. Interactions of the SH2 domain of lymphocyte-specific tyrosine protein kinase p56lck with phosphotyrosine-containing proteins.
Peri KG; Gervais FG; Weil R; Davidson D; Gish GD; Veillette A
Oncogene; 1993 Oct; 8(10):2765-72. PubMed ID: 7690927
[TBL] [Abstract][Full Text] [Related]
14. Novel tyrosine phosphorylations accompany the activation of pp60c-src during chemical carcinogenesis.
Kanner SB; Gilmer TM; Reynolds AB; Parsons JT
Oncogene; 1989 Mar; 4(3):295-300. PubMed ID: 2468123
[TBL] [Abstract][Full Text] [Related]
15. Differential binding of pp60c-src and pp60v-src to cytoskeleton is mediated by SH2 and catalytic domains.
Okamura H; Resh MD
Oncogene; 1994 Aug; 9(8):2293-303. PubMed ID: 7518578
[TBL] [Abstract][Full Text] [Related]
16. Mutational activation of pp60(c-src) leads to a tumorigenic phenotype in a preneoplastic Syrian hamster embryo cell line.
Lansing TJ; Turk BF; Kanner SB; Gilmer TM
Cancer Res; 1997 May; 57(10):1962-9. PubMed ID: 9157992
[TBL] [Abstract][Full Text] [Related]
17. Increased levels of p21ras-GTP and enhanced DNA synthesis accompany elevated tyrosyl phosphorylation of GAP-associated proteins, p190 and p62, in c-src overexpressors.
Chang JH; Wilson LK; Moyers JS; Zhang K; Parsons SJ
Oncogene; 1993 Apr; 8(4):959-67. PubMed ID: 7681161
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine phosphorylation of caveolin-2 at residue 27: differences in the spatial and temporal behavior of phospho-Cav-2 (pY19 and pY27).
Wang XB; Lee H; Capozza F; Marmon S; Sotgia F; Brooks JW; Campos-Gonzalez R; Lisanti MP
Biochemistry; 2004 Nov; 43(43):13694-706. PubMed ID: 15504032
[TBL] [Abstract][Full Text] [Related]
19. Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav.
Katzav S
Oncogene; 1993 Jul; 8(7):1757-63. PubMed ID: 8510922
[TBL] [Abstract][Full Text] [Related]
20. SH2 mutants of c-src that are host dependent for transformation are trans-dominant inhibitors of mouse cell transformation by activated c-src.
Hirai H; Varmus HE
Genes Dev; 1990 Dec; 4(12B):2342-52. PubMed ID: 1703982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
